Yasoo Health, Inc. Receives Nearly $1 Million to Develop Novel Nutritional Formulation

JOHNSON CITY, Tenn., Feb 07, 2006 /PRNewswire via COMTEX/ -- Yasoo Health, Inc. announced today that it received $936,375 in financing from the Cystic Fibrosis Foundation* to develop and commercialize a "first of its kind" formulation that addresses a key nutritional problem of poor fat-soluble vitamin and nutrient absorption in cystic fibrosis (CF) patients.

This novel, antioxidant rich formulation aims to overcome malabsorption of fat-soluble vitamins and other compounds and improve the nutritional and antioxidant status of CF patients. Studies indicate that many CF patients have lower than normal blood levels of key fat-soluble vitamins and antioxidants despite standard supplementation. Research suggests that improved nutritional and antioxidant status and decreased oxidative stress can improve clinical outcomes in cystic fibrosis. "Optimal nutrition remains one of the best tools CF patients have to hold back progression of their disease. However, current vitamin supplements for CF could be more effective if made more absorbable - that's why we support the development of this innovative Yasoo product," said Preston Campbell, M.D., and Executive VP Medical Affairs of the Cystic Fibrosis Foundation.

Yasoo Health, a research company focusing on the role of nutrients and natural compounds in the management of chronic disease, developed a liquid prototype formulation encompassing a technology to help overcome nutrient malabsorption in this population under a Small Business Innovation Research grant from the National Institutes of Health. This formulation was clinically evaluated at the University of Colorado Children's Hospital and the results were presented at 2005 North American Cystic Fibrosis Conference. The results showed that key fat-soluble vitamins and nutrients were readily absorbed and that levels were normalized in these patients.

Dr. Andreas Papas, President of Yasoo Health, will serve as the Principal Investigator of this project. "We are honored that the Cystic Fibrosis Foundation has given us the opportunity to commercialize a product that we hope will advance the standard of nutritional care of cystic fibrosis patients, " said Papas. "We plan to evaluate further initial observations suggesting that this product may provide clinically meaningful benefits." This funding will allow Yasoo Health to further develop this product, both in liquid and softgel formats, to better meet the needs of CF patients.

Yasoo Health, headquartered in Johnson City, Tennessee, seeks to develop proprietary, disease-specific products that will aid in the effective management of chronic diseases. Yasoo Health's research program integrates three major fields of knowledge including 1) clinical and medical science as it relates to the role of nutrients and phytochemicals in disease management, prevention, wellness and quality of life 2) formulation technology as it relates to the development of products to address specific needs of each market segment and 3) identification, extraction and/or synthesis of high value, naturally occurring compounds.

*The mission of the Cystic Fibrosis Foundation, a donor-supported, nonprofit organization, is to assure the development of the means to cure and control cystic fibrosis and to improve the quality of life for those with the disease. The Cystic Fibrosis Foundation Therapeutics, Inc.(CFFT) is the nonprofit drug discovery and development affiliate of the CF Foundation. The CF Foundation provides total support to CFFT. For more information about cystic fibrosis, the CF Foundation or CFFT, visit www.cff.org , or call (800) FIGHTCF.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.